Results 1 to 10 of about 13,748 (197)

NTRK expression and its clinical significance in pancreatic neuroendocrine tumors [PDF]

Discover Oncology
Background The neurotrophic TRK family, which includes NTRK1, 2, and 3, could be the oncogenic driving force in various cancers, when they undergo fusion mutations with other genes and form a chimeric oncoprotein.
Pingping Yan, Xiaoqin Dai, Fenfen Zhang, Yu Dong, Huijuan Shi, Anjia Han   +5 more
doaj   +2 more sources

Sructural rearrangements of NTRK genes: characteristics, methods of detection and targeted therapy for cancer

Сибирский онкологический журнал, 2022
Background. The first-generation trk inhibitors, larotrectinib and entrectinib, were approved by the u.s. Food and drug administration (Fda) for the treatment of advanced solid tumors harboring NTRK gene fusions in November 2018 and in august 2019 ...
A. A. Kechin, A. I. Andriyanova, M. L. Filipenko   +2 more
doaj   +1 more source

전이성 대장암의 새로운 표적치료

The Ewha Medical Journal, 2021
Over the past decade, substantial advances have been made in the individualization of therapeutic strategies for metastatic colorectal cancer (mCRC).

doaj   +1 more source

Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.

PLoS ONE, 2022
The clinical profiles and outcomes of patients with neurotrophic tropomyosin receptor kinase fusion-positive (NTRK+) solid tumors receiving standard of care other than tropomyosin receptor kinase inhibitor (TRKi) targeted therapy have not been well ...
Derrek P Hibar, George D Demetri, Solange Peters, Jessica Davies, Olivier Humblet, Sophia L Maund, Laura Perez   +6 more
doaj   +1 more source

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

Drugs in Context, 2022
Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1–2% and 0.2% of unselected NSCLC samples, respectively; however, their frequency is
Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain J Gelibter   +4 more
doaj   +1 more source

Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China

npj Precision Oncology, 2023
Neurotrophic tyrosine kinase (NTRK) fusions involving NTRK1, NTRK2, and NTRK3 were found in a broad range of solid tumors as driver gene variants. However, the prevalence of NTRK fusions in Chinese solid tumor patients is rarely reported.
Yujun Xu, Xiaoliang Shi, Weifeng Wang, Lin Zhang, Shinghu Cheung, Marion Rudolph, Nicoletta Brega, Xiaowei Dong, Lili Qian, Liwei Wang, Shaohua Yuan, Daniel Shao Weng Tan, Kai Wang   +12 more
doaj   +1 more source

NTRK fusion protein expression is absent in a large cohort of diffuse large B-cell lymphoma

Frontiers in Oncology, 2023
BackgroundEven though two NTRK-targeting drugs are available for the treatment of irresectable, metastatic, or progressive NTRK-positive solid tumors, less is known about the role of NTRK fusions in lymphoma.
Susanne Ghandili, Judith Dierlamm, Carsten Bokemeyer, Clara Marie von Bargen, Sören Alexander Weidemann   +4 more
doaj   +1 more source

NTRK-fusion associated sarcoma: Identification of two cases with a distinct perineurioma-like pattern

Human Pathology Reports, 2022
Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are oncogenic drivers found in a few rare tumours. However, NTRK rearrangements are being increasingly identified in a range of soft tissue neoplasms. Recognition of NTRK fusion-driven sarcomas is
Vanessa Young, Daniel Wong, Max Yan, Fiona Maclean   +3 more
doaj   +1 more source

Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project

Cancer Treatment and Research Communications, 2022
Introduction: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. Limited data exist on the overall survival (OS) of patients with tumors with NTRK gene fusions and on the co-occurrence of NTRK fusions ...
John Bridgewater, Xiaolong Jiao, Mounika Parimi, Clare Flach, Jeran Stratford, Atanas Kamburov, Arndt A. Schmitz, Jihong Zong, John A. Reeves, Karen Keating, Amanda Bruno, Marc Fellous, Mariana Buongermino Pereira, Lyudmila Bazhenova   +13 more
doaj   +1 more source

Precision oncology: the intention-to-treat analysis fallacy. [PDF]

, 2020
It has recently been suggested that precision oncology studies should be reanalysed using the intention-to-treat (ITT) methodology developed for randomized controlled clinical trials.
Kato, Shumei, Kurzrock, Razelle, Okamura, Ryosuke, Sicklick, Jason K   +3 more
core   +1 more source